Briacell Therapeutics Corp

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Receives FDA Clearance to Initiate Bria-BRES+(TM) Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting